SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial

Condition:   Heart Failure With Preserved Ejection Fraction Interventions:   Drug: Empagliflozin + Potassium Chloride;   Drug: Empagliflozin + Potassium Nitrate;   Drug: Potassium Chloride + Placebo for Empagliflozin Sponsor:   University of Pennsylvania Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials